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The complement system is well known for its role in innate immunity and in maintenance of tissue homeostasis,
providing a first line of defence against infection and playing a key role in flagging apoptotic cells and debris for
disposal. Unfortunately, complement also contributes to pathogenesis of many diseases, in some cases driving
pathology, and in others amplifying or exacerbating the inflammatory and damaging impact of non-complement
disease triggers. The driving role of complement in a single disease, paroxysmal nocturnal hemoglobinuria
(PNH), provoked the development and eventual FDA (US Food and Drug Administration) approval of eculi-
zumab (Soliris™), an anti-C5 antibody, for therapy. Although PNH is very rare, eculizumab provided clinical
validation and demonstrated that inhibiting the complement system was not only well-tolerated, but also pro-
vided rapid therapy and saved lives. This clinical validation, together with advances in genetic analyses that
demonstrated strong associations between complement and common diseases, drove new drug discovery pro-
grammes in both academic laboratories and large pharmaceutical companies. Numerous drugs have entered
clinical development and several are in phase 3 trials; however, many have fallen by the wayside. Despite this
high attrition rate, crucial lessons have been learnt and hurdles to development have become clear. These in-
sights have driven development of next generation anti-complement drugs designed to avoid pitfalls and fa-
cilitate patient access. In this article, we do not set out to provide a text-heavy review of complement ther-
apeutics but instead will simply highlight the targets, modalities and current status of the plethora of drugs
approved or in clinical development. With such a fast-moving drug development landscape, such a compendium
will inevitably become out-dated; however, we provide a snapshot of the current field and illustrate the in-
creased choice that clinicians might enjoy in the future in selecting the best drug for their application, decisions
based not only on efficacy but also cost, mechanistic target, modality and route of delivery.
1. Complement plays a key role in immune defence and tissue
homeostasis
Complement, a key arm of the immune system, is a protein cascade,
triggered by specific recognition molecules and progressing through a
series of protein/protein interactions that culminate in the formation of
a cytolytic pore (Holers, 2014; Merle et al., 2015). Efficient amplifica-
tion on pathogens ensures an effective response (Harrison, 2018;
Lachmann, 2009). Complement proteins are largely generated by the
liver and are abundant in plasma (up to 5% total protein), although
many are also produced, sometimes exclusively, at extra-hepatic sites
(Morgan and Gasque, 1997). The entire cascade progresses from C1
activation through to membrane attack complex (MAC) formation, in-
teractions dictated by de novo binding sites revealed following protein
conformational changes resulting from proteolytic cleavage of the cir-
culating, native protein (C3, C4, C2, FB, C5) or as a consequence of
unfolding (C9) or protein/protein interaction (C6-C9).
The classical pathway (CP) is initiated when antigen-antibody
complexes bind the recognition moiety, C1q, triggering activation of
the associated proteases, C1r and C1s. Activated C1s cleaves C4 to C4b
which binds covalently through its thioester to the target and there
captures C2 which is also cleaved by C1s to form the CP C3 convertase
C4b2a. The lectin pathway (LP) differs from the CP only in the re-
cognition/initiation unit which binds to bacterial sugars, lectins such as
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mannose binding lectin (MBL), ficolins or collectins. All bind carbo-
hydrate epitopes, triggering activation of the associated proteases
MASP1 and MASP2, the latter cleaving C4 and C2 to form C4b2a (Endo
et al., 2015; Farrar et al., 2016). C4b2a cleaves C3 to C3b, exposing the
internal thioester that covalently binds C3b to surfaces, causing acti-
vating surfaces to become densely coated in C3b (opsonised), providing
ligands for phagocyte uptake of the target, a crucial defence against
infection. C3b also associates with the C3 convertase to create the C5
convertase C4b2a3b.
The alternative pathway is initiated by C3b (generated from the
activation pathways or non-specific sources) binding factor B (FB),
which is then cleaved by factor D (FD) to form the C3 convertase,
C3bBb. C3bBb cleaves C3 to C3b, coating adjacent surfaces and gen-
erating a C5 convertase, C3bBbC3b. Tickover activation of C3 in the
fluid phase primes the system for rapid amplification on activating
surfaces (Harrison, 2018; Lachmann et al., 2018), typified by absence of
the regulatory proteins that suppress activation on self cells (Morgan
and Meri, 1994). FB can bind to any C3b deposited on an activating
surface, including that resulting from activation of the classical and
lectin pathways. Thus, the alternative pathway is known as the am-
plification loop of the complement cascade and plays a crucial role in
amplifying any small trigger to a large downstream response.
The terminal pathway begins with the capture and cleavage of C5
by either of the C5 convertases, releasing a proinflammatory peptide,
C5a. C5b remains attached to the convertase and binds sequentially C6
and C7 and, after release of C5b67 from the convertase and association
with membrane, C8 and C9 bind to form the lytic MAC. Recent studies
have illustrated the structural complexity of the MAC pore (Hadders
et al., 2012; Menny et al., 2018; Serna et al., 2016). Notably, while MAC
efficiently lyses aged (or unprotected) erythrocytes and susceptible
bacteria, when formed on nucleated self-cells it triggers a plethora of
activation events, many of which are highly pro-inflammatory
(Triantafilou et al., 2013).
Complement regulatory proteins include plasma proteins factor H
(FH) and C4b-binding protein (C4bp) and membrane proteins, CD35,
CD46 and CD55 that inhibit the C3/C5 convertases. Control of the
enzymes is brought about by decay accelerating activity, characterised
by binding of control proteins, such as FH or CD55, to the multi-
molecular convertases and rapid dissociation of the enzymatic subunit,
Bb or C2a. The C3b or C4b that remains is subject to cofactor activity
where regulatory proteins bind the remaining subunit, enabling a
complement serine protease, factor I (FI) to cleave and inactivate the
substrate forming iC3b/C3dg or C4d/C4c. The MAC inhibitor CD59
blocks formation of the lytic pore as soon as C8 is bound to the complex,
thus preventing polymerisation of C9. Together these control proteins
control complement activation on self-tissues (Holers, 2014; Merle
et al., 2015; Morgan and Meri, 1994).
Complement receptors bind the degradation fragments of C3 and
C4, providing an additional route for immune defence. The activation
fragments C3a and C5a, bind receptors (C3aR/C5aR1/C5aR2) on nu-
merous cell types to trigger diverse responses, ranging from neutrophil
recruitment and activation, to priming of endothelial cells to enhance
adhesion (Coulthard and Woodruff, 2015; Wetsel, 1995). C5a/C5aR
interactions activate the NLRP3 (NOD-, LRR- and pyrin domain-con-
taining 3) inflammasome, impact T cell responses in adaptive immunity
and play a multitude of other roles (Arbore and Kemper, 2016;
Triantafilou et al., 2013). The receptors CR3 and CR4 on phagocytic
cells bind iC3b to promote uptake and clearance of opsonised targets,
while C3dg engages CR2 on B cells and follicular dendritic cells (FDCs)
to amplify the immune response to opsonised antigens (Carroll and
Isenman, 2012; Dempsey et al., 1996). As a consequence of these in-
teractions, complement is intricately entwined in numerous and com-
plex ways with all arms of immunity and host defence (Arbore et al.,
2017; Kolev et al., 2014).
2. Understanding roles of complement in disease fuels drug
discovery
Complement dysregulation occurs when the activation and con-
trol mechanisms of complement that together play crucial roles in
maintaining health and tissue homeostasis fail; when the delicate bal-
ance between activation and control is disturbed, tissue damage and
disease ensue (Ricklin and Lambris, 2013; Ricklin et al., 2016;
Rodriguez de Cordoba et al., 2012). This dysregulation can be a con-
sequence of autoantibodies against regulatory proteins preventing
complement control (Brocklebank et al., 2017; Goodship et al., 2012;
Paixao-Cavalcante et al., 2012), or gene mutations or polymorphisms in
complement proteins leading to altered expression or function (Harris
et al., 2012; Heurich et al., 2011; Rodriguez de Cordoba et al., 2012).
Autoantibodies against tissue antigens can also drive inappropriate
complement activation and damaged tissue drives further activation
and dysregulation in a vicious cycle of inflammation and tissue damage.
Complement involvement in disease has been recognised for
more than 50 years, particularly in diseases such as rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE) (Schur and Austen, 1968)
Table 1
Abbreviations used for diseases in text, tables and figures.
Abbreviation Disease
AAV Anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis
AD Alzheimer’s disease
aHUS Atypical hemolytic uremic syndrome
AKI Acute kidney injury
AMD Age-related macular degeneration
AMR Antibody-mediated rejection
APS Antiphospholipid syndrome
ARDS Acute respiratory distress syndrome
BD Berger’s disease
BP Bullous pemphigoid
C3G C3 glomerulopathy
C3GN C3 glomerulonephritis
CAD Cold agglutinin disease
COPD Chronic obstructive pulmonary disease
CPB Cardiopulmonary bypass
DDD Dense deposit disease
DGF Delayed graft function
GA Geographic atrophy
GBS Guillain-Barré syndrome
gMG Generalized myasthenia gravis
GPA Granulomatosis with polyangiitis
GVHD Graft versus host disease
HAE Hereditary angioedema
HS Hidradenitis suppurativa
HSCT-TMA Hematopoietic stem cell transplant-related thrombotic
microangiopathy
IgAN IgA nephropathy
I/R Ischemia/reperfusion
IC-MPGN Immune complex-mediated membranoproliferative
glomerulonephritis
IMNM Immune Mediated Necrotizing Myopathy
IPCV Idiopathic polypoidal choroidal vasculopathy
KT Kidney transplant
LN Lupus nephritis
MN Membranous nephropathy
MPA Microscopic polyangiitis
MS Multiple sclerosis
NMO (NMOSD) Neuromyelitis optica (spectrum disorder)
PG Pyoderma Gangrenosum
PNH Paroxysmal nocturnal hemoglobinuria
RA/OA Rheumatoid arthritis/Osteoarthritis
SIRS Systemic inflammatory response syndrome
SLE Systemic lupus erythematosus
STGD1 Stargardt Disease 1
SVS, SS Severe sepsis, septic shock
TMA Thrombotic microangiopathy
wAIHA Warm type autoimmune hemolytic anemia
wAMD Wet AMD
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(see Table 1 for all disease abbreviations). Despite this recognition,
there was some resistance to therapeutic targeting of the system based
on concern that blocking a crucial arm of innate immunity would be
unsafe (Harris, 2018). The demonstration that MAC caused haemolysis
in the ultra-rare disease paroxysmal nocturnal hemoglobinuria (PNH)
broke this resistance and led to the development of the blockbuster
MAC-blocking anti-C5 drug, eculizumab (Rosse and Dacie, 1966).
Eculizumab, a game-changer therapy, was approved by the Food and
Drug Administration (FDA) for treatment of PNH in 2007, some 40
years after the recognition that complement caused this devastating
disease (Rother et al., 2007). Approval of eculizumab for PNH therapy
brought much needed clinical validation and demonstrated that
blockade of complement could be achieved relatively safely and bring
about profound and life-changing results. Eculizumab was the first drug
to be approved that blocked the complement pathway completely at a
specific point, the only other complement drugs currently approved for
therapy have been replacement therapies for C1inh (Berinert, Cinryze,
Ruconest) in hereditary angioedema (HAE) where C1inh deficiency
causes dysregulation of the complement and kinin systems (Csuka et al.,
2017; Morgan, 2010). The slow progress along the road to approval for
anti-complement drugs evidences the complexities of successful drug
development for inhibition of an abundant and important effector
system; many of the barriers to progress remain today.
Common complement driven diseases really came to prominence
in 2005 when frequent polymorphisms in FH were shown to dictate risk
for the common blinding disease, age-related macular degeneration
(AMD) (Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005). At
that time, eculizumab was proving successful in clinical trials for PNH
and the suggestion that complement dysregulation was driving this
common blinding disease triggered an explosion of interest, with nu-
merous biotechnology and pharmaceutical companies initiating anti-
complement drug discovery programmes. FDA approval for eculizumab
in the rare renal disease atypical haemolytic uremic syndrome (aHUS)
in 2011 fuelled this frenzy, with a procession of new drugs in devel-
opment and clinical trials over the last few years (Brodsky et al., 2008;
Harris et al., 2018; Morgan and Harris, 2015; Ricklin et al., 2018). Not
surprisingly, the focus for these new drugs has remained PNH and
aHUS, diseases where complement is the primary driver of disease and
in which complement inhibition has been validated (Harris et al.,
2018). The list of diseases (illustrated in Fig. 1) has expanded to include
AMD and many other pathologies where complement is known to play a
role. These include generalised myasthenia gravis (gMG) where eculi-
zumab was approved by FDA and European regulators in 2017 and
Neuromyelitis optica spectrum disorder (NMOSD), which was approved
by the FDA in June 2019.
The success of eculizumab in the treatment of PNH and aHUS
demonstrates that the terminal pathway is the driving force that da-
mages and/or activates the target cells in these rare diseases. The tis-
sues inappropriately under attack, respectively blood cells, particularly
erythrocytes, and endothelial cells, are readily accessible to the drug as
they are exposed to plasma; thus, it is perhaps not surprising that these
diseases can be effectively treated using systemic C5 blockade. Many
other diseases are driven by complement dysregulation, as illustrated in
Fig. 1. These include the renal disease C3 glomerulopathy (C3G), the
neurological disease NMOSD, the neuromuscular disease gMG and the
blinding disease AMD; all are target indications for a growing number
of anti-complement drugs. The evidence for other diseases is rapidly
building and a strong case can be made for anti-complement therapies
in diverse diseases, including iatrogenic and surgery-related conditions.
Increased levels of complement biomarkers in plasma and disease-re-
levant fluids, such as synovial fluid and cerebrospinal fluid, or com-
plement deposition in tissues, indicate that complement is abnormally
activated, although whether this is cause or effect of disease may need
further investigation. Genetic associations with disease, positive read-
outs from animal models and evidence from clinical studies all combine
to support a role of complement in pathogenesis and validate specific
diseases as targets for therapy (Harris et al., 2018; Ricklin and Lambris,
2013; Ricklin et al., 2016).
Challenges, pitfalls and risks associated with blockade of a key
arm of innate immunity accompany this growth in the scope of anti-
complement therapies (Harris, 2018). For example, opsonisation and
bacteriolytic activity can be severely compromised, increasing risk of
infection (Socie et al., 2019). Additionally, for most complement pro-
teins, target concentration is high, necessitating huge doses of drug,
particularly if an individual is in the acute phase of an illness or injury
that further increases plasma levels of many complement proteins.
Fig. 1. Complement activation is implicated in numerous
diseases. Complement exists in a delicate balance between
activation and regulation. When that balance becomes dis-
turbed, tissue can be damaged and disease ensues.
Complement is implicated in many different diseases although
in many cases it acts to exacerbate a cycle of inflammation
induced by other triggers or causes; anti-complement therapy
may have a role to play in treatment of these diseases. In some
cases, such as PNH, aHUS and C3G, complement is the main
driver of disease. These diseases are more prevalent in clinical
trial and are indicated in red in the figure. Anti-complement
therapy is thought to play a key role in the treatment of these
diseases. Refer to Table 1 for all disease abbreviations. Car-
toons from PRESENTERMEDIA (www.presentermedia.com).
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Tissue damage may be mediated by locally produced complement, ra-
ther than systemic complement, meaning that tissue access of the drug
is critical. These factors, together with the wide normal ranges of target
proteins found in the general population, mean that complement
blockade, and particularly the optimal goal for many diseases of mod-
ulating complement rather than completely blocking, is challenging.
New ways to overcome these challenges are emerging with next gen-
eration drugs progressing through clinical trials as described below.
The aim of this article is neither to review complement and disease
nor the drug development process; many outstanding recent reviews
cover these areas and are cited above. Rather we will provide a snap-
shot of the current status of the field, highlighting those drugs which
are in clinical development or approved, and next generation ap-
proaches bringing forward new complement targets, applications,
modalities and routes of administration (Tables 2a and 2b ).
3. Next generation drugs
Eculizumab has proven very effective in PNH and aHUS; why
then are so many of the new drugs entering clinical development also
targeting these diseases, often even targeting the same element of the
complement system? The answer is, of course, that it is a safe bet.
Approval of eculizumab was a major milestone for the field, providing
long-sought clinical validation for complement inhibition in man. There
are, however, drawbacks associated with this drug, including high cost,
risk of meningococcal infection, frequency and amount of dosing, route
of administration and difficult pharmacokinetics as the target C5 can
increase in concentration under conditions of acute phase, resulting in
break-through symptoms. There are also clinical issues with the use of
eculizumab; indeed, in PNH, while major life-threatening complica-
tions, such as thrombotic events, are well-treated, a substantial pro-
portion of patients remain transfusion-dependent on eculizumab
(Hillmen et al., 2013). PNH erythrocytes lack CD55 (decay accelerator)
as well as CD59 (MAC blocker), therefore complement continues to
amplify. As the cells are no longer removed from the circulation by
MAC mediated lysis, they accumulate activated C3 on their surfaces and
are subject to haemolysis due to phagocytic uptake in the extravascular
space (Risitano et al., 2009). Problems such as these, together with the
ambition to expand the number of indications treated with anti-com-
plement drugs, have driven the development landscape illustrated in
Table 3 and Fig. 2. Novel and innovative ways of inhibiting complement
that move beyond C5 and ultra-rare diseases and circumvent the
challenges associated with complement inhibition are evolving; these
second generation high-potential drugs are rapidly progressing through
phase 2 clinical trials and are likely to challenge eculizumab and
change the field in the near future (Fig. 3). Both drugs targeting C5 (in
ways that differentiate from eculizumab) and therapeutics targeting
other components and pathways of complement are progressing
through clinical development. Indeed, a next-generation ‘recycling’
form of eculizumab, termed ravulizumab (Ultomiris™) (Sheridan et al.,
2018), has been FDA- and EMA-approved for PNH, is under fast-track
review for aHUS and is completing phase 3 trials in gMG; however, no
other new drugs have yet made it past phase 3.
Innovations in next generation drugs are wide and varied.
Recycling or ‘pH-switched’ antibodies can be generated from existing
antibodies by modifying the antigen-binding region, frequently by in-
corporating histidine residues, such that the antibody while retaining
high affinity for target at pH 7.4, loses affinity in the acidic pH 6.0
environment of the endosome (below the isoelectric point of histidine).
When antibody is passively internalised into endothelial cells, the pH
drop in the endosome results in disengagement of the target and re-
cycling of the ‘empty’ antibody back to the circulation (Igawa et al.,
2010). This process improves the pharmacokinetic properties of the
drug, enabling less frequent dosing. Ravulizumab, the next generation
‘recycling’ form of eculizumab, is administered in PNH every 8 weeks,
rather than every 2 weeks, although the dose is much higher (3.3 g IV
contrasting to 0.9 g IV for eculizumab), a negligible saving on overall
drug dose! Another recycling anti-C5 antibody is currently in phase 2
development, crovalimab (Roche; SKY59); this antibody was selected
during the original screening process for its recycling or pH-switched
properties (Fukuzawa et al., 2017; Sampei et al., 2018). Crovalimab is
being developed as a SC-administered agent and dosing schedules in
reported trials suggest that a lower dose (340mg every two weeks) was
effective (Risitano et al., 2019). Crovalimab is also effective in patients
carrying the R885H C5 variant (common in Japan), resistant to eculi-
zumab inhibition. A different approach to decrease drug dose is to
develop an agent that binds neoepitopes on complement proteins rather
than targeting the native protein. Various drugs are in clinical devel-
opment, including IFX-1 (InflaRx), which binds the released C5a frag-
ment (Riedemann et al., 2017), and the preclinical antibody, BIVV020
(Sanofi), reported as binding activated C1s.
Route of administration is a critical consideration. The move
from IV administration to SC or even oral administration has been ra-
pidly progressing. As well as crovalimab, noted above, several peptide-
based anti-complement drugs are being administered SC, including
APL-2 (C3 inhibitor; Apellis), AMY101 (C3 inhibitor; Amyndas) and
zilucoplan (C5 inhibitor; RaPharma). Some small biologics, such as
nomacopan (C5 inhibitor; Akari), are also administered SC, and various
strategic partnerships announced in company press releases in recent
times (for example, Zealand Pharma and Alexion) reveal an expanding
pipeline of SC drugs. Avacopan (Chemocentryx), an orally active in-
hibitor of C5aR1, is in phase 3 for antineutrophil cytoplasmic anti-
bodies (ANCA)-associated vasculitis (AAV) and in phase 2 for a number
of other indications (Table 3) (Bekker et al., 2016). Other orally
Table 2b
Drugs in preclinical development, only drugs where the target has been disclosed are included. Route of administration is not included for preclinical assets.
DRUGS IN PRECLINICAL DEVELOPMENT
Drug name Company Target Modality
Name not disclosed RaPharma FD Peptide
OMS906 Omeros MASP3 Ab
BIVV020 Sanofi activated C1s Ab
Name not disclosed RaPharma C1s Peptide
AMY-201, ‘mini-factor H’ Amyndas Contains functional domains of FH;
complement modulator
Biologic
PRO-02 Prothix BV C2 Ab
IFX2 InFlaRx C5a Ab
SOBI005 SOBI C5 Affibody
Name not disclosed (oral) RaPharma C5 SM
Zilucoplan extended release RaPharma C5 Peptide
CP010 Complement
Pharma/Alexion
C6 Ab
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bioavailable drugs are progressing through phase 2 with a focus on the
amplification loop. LNP023 (Novartis) blocks FB and is in clinical trials
(oral route twice daily) for a number of indications including PNH and
renal disease (Schubart et al., 2019). Achillion’s SM FD inhibitors are
also being tested in these indications, although the target has a very
high synthesis rate (1.33mg/kg/day) (Pascual et al., 1988),
Table 3
Drugs in current clinical trial. Each line represents a clinical trial and these are shaded according
to the phase of development. Only company-sponsored trials are indicated and completed trials are
excluded. text indicates that a drug has already been approved for treatment of a different
indication and is being trialled for a new purpose. For disease abbreviations refer to Table 1. For
modality and route of administration please refer to Table 2a and 2b.
HV; healthy volunteer.
*Recently approved by FDA for NMOSD, June 2019.
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necessitating thrice daily oral administration. Other oral drugs are in
preclinical development, including RaPharma’s SM targeting C5. Such
orally-bioavailable SM drugs, including targets within the amplification
loop and C5, are likely to change the landscape of complement drug
development in the years to come. While the required dosing may be
frequent, due to target concentration or turnover, the oral route and
ability to rapidly reverse inhibition by stopping treatment in the face of
infection or other complication may be of huge benefit.
Targeting at the nucleotide level offers a different approach to
overcome the challenge of high target concentration and drug dose, the
goal is to prevent translation of the protein and thus its release to the
blood stream. Alnylam and Ionis have led the way with, respectively,
C5 RNAi (ribonucleic acid interference; cemdisiran) and FB antisense
oligonucleotide (ASO), both in phase 2, the former for IgA nephropathy
(IgAN) and the latter for AMD (Grossman et al., 2017; Kusner et al.,
2019). Cemdisiran was originally trialled in PNH and although it suc-
cessfully blocked synthesis of C5 to 98% the trace residual C5, possibly
generated extra-hepatically, resulted in some lysis with lactate dehy-
drogenase (LDH) ˜ 1.5 times upper limit of normal (ULN; press release
December 5th 2016). Generation of complement components by tissues
outside of the liver, such as FD by adipocytes, C7, C1q and properdin by
cells of monocytic lineage, can limit utility of this liver-targeting ap-
proach. Many tissues, including the central nervous system (CNS) and
the joint can generate all components of the complement cascade,
particularly when cells are under the influence of inflammatory cyto-
kines. Even when the liver contributes the majority of a specific protein,
local biosynthesis may be the driver of disease or pathology, for ex-
ample in kidney transplant (Farrar et al., 2006; Pratt et al., 2002); this
may stymie anti-sense approaches targeting hepatic synthesis.
Local and ‘targeted’ inhibition of complement has been the
driver behind a number of innovative drugs which deliver therapy to
tissues; various targeting moieties have been reported, some of which
bind C3 fragments and others that bind epitopes exposed on damaged
tissues (Holers et al., 2013, 2016; Ruseva et al., 2015). TT30, initially
developed by Taligen Therapeutics and taken through phase 1 testing
by Alexion in PNH (Fridkis-Hareli et al., 2011), is a chimeric molecule,
with one arm binding complement activation fragments in tissues, and
the second arm comprising the complement regulator domain, here the
amino-terminal portion of FH. This agent homes to the tissue under
attack, delivering lasting therapy, while excess agent is excreted or
Fig. 2. Anti-complement drugs currently in
clinical development. The concentric rings
indicate the different phases of clinical devel-
opment, with ‘approved’ in the centre. Only
drugs currently in clinical development are
shown and the most advanced stage of devel-
opment for any indication is shown; trials
posted but not yet recruiting are included.
Colouring and shape indicate modality and
route of administration. There are a number of
drugs in clinical development, indicated as
preclinical or first-time-in-human on company
websites (Gyroscope Therapeutics, Gemini
Therapeutics and others), these are only in-
cluded in this diagram if targets have been
disclosed. The inclusion of C1inh drugs in this
figure reflects their repurposing for comple-
ment-mediated complications of kidney trans-
plant.
Fig. 3. Development of next generation drugs.
The pyramid indicates the potential path of travel for ‘next generation’ anti-
complement drugs. Early drugs have been dosed at high levels, often in-
travenously, with the aim to totally block the pathway. Later drugs have longer
duration of action and/or can be administered subcutaneously or orally. Some
drugs in, or approaching, clinical development may have the capacity to
modulate the system rather than turn it off altogether. The potential to localise
therapy to the tissue in need using gene therapy or ‘homing’ agents presents
exciting possibilities. Towards the pinnacle of the pyramid lie future drugs,
currenty speculation; drugs which can cross the blood brain barrier (BBB) or
other obstacles, that can reverse dysregulation and restore homeostasis, or that
can modulate disease outcome by impacting other arms of the immune system
or other biological cascades. Cartoons from PRESENTERMEDIA (www.
presentermedia.com).
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metabolised. Such agents have several advantages, not only should they
decrease dose of drug as they target activated complement, not native
proteins, but they should also lower risk of infection as systemic in-
hibition is transient. TT30 has not progressed beyond phase 1 but
various similar agents remain in preclinical development. A number of
companies have reported development of gene therapy-based agents for
treatment of AMD (for example, Gyroscope Therapeutics https://
gyroscopetx.com/; Gemini Therapeutics https://www.
geminitherapeutics.com/), with exciting potential for local therapy,
but the nature of these drugs and their targets are not disclosed.
Crossing barriers presents a particular problem for CNS diseases; to
date, none of the drugs in development has been selected for capacity to
cross the blood-brain barrier (BBB) and access the CNS; given that
complement has been implicated in a number of CNS disorders, this is a
major unmet need (Carpanini et al., 2019). It is possible, although
difficult, expensive and risky, to inject or infuse drugs directly into the
intraventricular or intrathecal space. Thus, a number of approaches for
crossing the BBB are in development; these include the ‘trojan horse’
method of piggy-backing drugs onto peptides or antibodies that target
receptors, such as the transferrin receptor or insulin receptor. These
delivery methods are reviewed extensively elsewhere (Abdul Razzak
et al., 2019; Carpanini et al., 2019). Although not a complement target,
gene therapy targeting motor neurons was approved by the FDA in
2019 for treatment of spinal muscular atrophy in children (Zol-
gensma™) illustrating the potential for gene therapy in the CNS. This
drug utilises a non-replicating adeno-associated virus (AAV9) vector
that can cross the BBB to deliver the target gene. In a recent press re-
lease (July 18, 2019), Apellis announced the development of APL-9, a
PEGylated C3-inhibiting peptide designed to prevent rapid comple-
ment-mediated attack on AAV-based vectors and improve efficacy of
gene therapy.
Selecting and stratifying diseases and individual patients for
complement interventions will be challenging as the field expands be-
yond the ultra-rare complement-driven conditions. First, it will be ne-
cessary to demonstrate that complement activation is occurring in the
candidate disease; second it is important to consider heterogeneity –
that some patients with a particular disease label may have a highly
complement driven disease while others will not; interventions can only
work in the former group. As an example, multiple sclerosis, although
typified by CNS myelin loss and resultant functional deficits, en-
compasses a spectrum of disease types; pathological studies have shown
that complement deposits in brain are a major feature in about a third
of cases (Lucchinetti et al., 2000). Similarly, with the focus of anti-
complement therapy in renal disease, attention has focussed in recent
years on treatment of the devastating renal disease, C3G, for which
there is no FDA-approved therapy. Unlike in aHUS, it is thought that C3
dysregulation dominates in the fluid phase in C3G, with dysregulation
of surface-bound C5 convertase in a subset of patients. Case reports, and
a small clinical trial in the US (six patients) using eculizumab to treat
C3G, describe some improvement in a subset of patients (Lebreton
et al., 2017; Nester and Smith, 2016). Limited data on a heterogeneous
disease make therapeutic evaluation difficult, but improvement in renal
function may correlate with high plasma terminal complement complex
(TCC) levels pre-treatment and evidence of rapidly progressive or acute
crescentic disease (Le Quintrec et al., 2015). Recent guidance from NHS
England supports use of eculizumab in a tightly stratified group of post-
transplant patients with evidence of acute inflammation and disease
recurrence on kidney biopsy (Clinical Commissioning Policy, 2017).
Stratification and selection will be particularly important for clinical
trials, including only those patients with evidence of complement
dysregulation. Stratification can be based on complement activation
biomarkers, particularly activation fragments and complexes, in plasma
or other biological fluids, as recently described for predicting progres-
sion in Alzheimer’s disease (Hakobyan et al., 2016).
How much inhibition is enough is an important and unanswered
question that will need to be addressed as complement therapeutics
become more widely used. In this context, PNH, the first disease target,
is unique in that complete inhibition of MAC formation is essential;
PNH erythrocytes are devoid of complement regulators and even a
small amount of free C5 in eculizumab-treated patients is sufficient to
cause breakthrough haemolysis (Kelly et al., 2008). In most other dis-
ease situations, turning down rather than turning off complement is
likely to be sufficient to confer therapeutic effect. The aim of treatment
would be to reverse dysregulation and restore homeostasis. In this
context, the amplification loop represents an excellent target. Reducing
cycling through the amplification loop by increasing loop regulation or
reducing availability of convertase could enable fine-tuning of therapy
to ameliorate pathology while retaining the protective roles of com-
plement in immune defence. This will be a significant advantage for
treating common diseases in elderly and infection-vulnerable in-
dividuals in the community. Several AP-specific drugs are in phase 2
development, including inhibitors of FB and FD. Other drugs which
have modulatory properties are on the horizon; homing agents de-
scribed above which deliver functional domains of regulators such as
FH can directly modulate the convertase enzymes, as can the preclinical
molecule AMY201 (Amyndas), a truncated, recombinant form of FH
engineered to bind with superior efficacy to target surfaces. Gene
therapies designed to boost the tissue’s ability to control complement at
disease sites have exciting potential to modulate. Finally, it may be
possible to block natural modifiers of complement; properdin stabilises
the AP convertase enzymes and MASP3 activates FD, interference at
these levels using drugs such as CLG561 (anti-properdin, Novartis) or
OMS906 (preclinical anti-MASP3, Omeros) may nudge the complement
system towards restored homeostasis. Importantly, anti-properdin in
animal models can have beneficial or detrimental effects depending on
the disease, highlighting the absolute requirement for full under-
standing of disease mechanism and appropriate patient stratification in
order to get the right drug into the right patient at the right time
(Ruseva et al., 2012; Ueda et al., 2018).
4. Concluding remarks
This article has sought to provide a snapshot of the anti-complement
drug landscape at the time of writing. The landscape is complex and fast
moving, so inevitably, there will be changes even by the time that this is
published. Nevertheless, we suggest that the Compendium captures the
complexities and direction of travel of the field and illustrates the
trends and assumptions that have shaped the field to date.
In the twelve years since the approval of eculizumab for PNH,
overnight transforming complement inhibition from an archaic interest
in animal models to a clinically tractable target in human disease, there
has been considerable activity, with many companies, large and small,
launching complement programmes and complement-targeted drugs;
however, progress to clinical use has been disappointing. Apart from
eculizumab, its successor ravulizumab and various takes on the ve-
nerable C1inh, nothing new has been approved, although intense ac-
tivity in clinical trial phases 2 and 3 predicts rapid change in the clinical
toolbox in the near future. The recent extension of Alexion’s key patents
in the US for eculizumab through to 2027 (press release August 15th
2017) may inhibit challengers in the C5 mAb space but other ap-
proaches to complement inhibition may, perversely, be prioritised and
accelerated.
Looking back, the view is more battlefield than landscape, littered
with the corpses of abandoned or failed drugs. In part, this carnage is a
result of an over-conservative “me too” approach that has focussed on
the very areas in which eculizumab has been successful – targeting C5
in PNH and other ultra-rare diseases; many of the survivors have sought
to diversify in terms of complement targets and, to some extent, disease
targets. Nevertheless, most remain focussed on ultra-rare or rare dis-
eases. The exception to date has been AMD, a relatively common dis-
ease where the genetics made the case for testing anti-complement
drugs. Although local (intravitreal) therapies have predominated to
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date, systemic approaches are also being explored; these may lay the
foundations for anti-complement drugs in other common and chronic
complement dysregulation diseases where there is considerable unmet
need.
Looking forward, there is every reason to be optimistic. There is
intense activity, many new Pharma entrants to the area, a broadening of
disease focus and a growing enthusiasm to move beyond C5 with some
innovative approaches that may reduce costs and address safety issues.
Belatedly, the field has realised that for most complement dysregulation
diseases – perhaps all except PNH – the aim should be to reduce not
eliminate complement activation in order to restore homeostasis. This
should be low risk, particularly with regard to bacterial infections, and
may open the door to orally active agents that will revolutionise the
field. Our expectation is for continued rapid progress and a landscape
that will, in just a few years, have changed beyond recognition.
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